Picture loading failed.

Anti-Zaire Ebolavirus GP therapeutic antibody (Pre-made Larcaviximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Larcaviximab is a chimeric (mouse/human) monoclonal antibody that can be potentially used in the treatment of Ebola Virus Infection.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-297-1mg 1mg 3090
GMP-Bios-ab-297-10mg 10mg 21890
GMP-Bios-ab-297-100mg 100mg 148000
GMP-Bios-ab-297-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-Zaire Ebolavirus GP therapeutic antibody (Pre-made Larcaviximab biosimilar,Whole mAb)
INN Name Larcaviximab
TargetZaire Ebolavirus GP
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure5ken:CD:GH:NO
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesMapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases
Conditions Approvedna
Conditions ActiveEbola virus infections
Conditions Discontinuedna
Development TechZmapp Technology